nodes	percent_of_prediction	percent_of_DWPC	metapath
Amphetamine—SLC22A5—Dactinomycin—melanoma	0.311	0.735	CbGbCtD
Amphetamine—CYP2D6—Vemurafenib—melanoma	0.112	0.265	CbGbCtD
Amphetamine—Monobenzone—TYR—melanoma	0.00998	0.563	CrCbGaD
Amphetamine—Tooth disorder—Temozolomide—melanoma	0.00483	0.0213	CcSEcCtD
Amphetamine—Digestion impaired—Temozolomide—melanoma	0.00469	0.0207	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Vemurafenib—melanoma	0.00401	0.0177	CcSEcCtD
Amphetamine—Speech disorder—Carmustine—melanoma	0.00377	0.0166	CcSEcCtD
Amphetamine—Accidental injury—Carmustine—melanoma	0.00366	0.0161	CcSEcCtD
Amphetamine—Speech disorder—Temozolomide—melanoma	0.00364	0.0161	CcSEcCtD
Amphetamine—Photosensitivity reaction—Vemurafenib—melanoma	0.00351	0.0155	CcSEcCtD
Amphetamine—Weight decreased—Vemurafenib—melanoma	0.00348	0.0153	CcSEcCtD
Amphetamine—Viral infection—Temozolomide—melanoma	0.00347	0.0153	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Vemurafenib—melanoma	0.0034	0.015	CcSEcCtD
Amphetamine—Injury—Bleomycin—melanoma	0.00293	0.0129	CcSEcCtD
Amphetamine—Erythema multiforme—Vemurafenib—melanoma	0.00291	0.0128	CcSEcCtD
Amphetamine—Cerebrovascular accident—Bleomycin—melanoma	0.00275	0.0121	CcSEcCtD
Amphetamine—Injury—Carmustine—melanoma	0.00256	0.0113	CcSEcCtD
Amphetamine—Pseudoephedrine—IL2—melanoma	0.00246	0.139	CrCbGaD
Amphetamine—Toxic epidermal necrolysis—Dactinomycin—melanoma	0.00226	0.00998	CcSEcCtD
Amphetamine—Affect lability—Temozolomide—melanoma	0.00224	0.00987	CcSEcCtD
Amphetamine—Anaphylactic shock—Vemurafenib—melanoma	0.00219	0.00964	CcSEcCtD
Amphetamine—Infection—Vemurafenib—melanoma	0.00217	0.00958	CcSEcCtD
Amphetamine—Mood swings—Temozolomide—melanoma	0.00215	0.0095	CcSEcCtD
Amphetamine—Weight decreased—Bleomycin—melanoma	0.00211	0.00929	CcSEcCtD
Amphetamine—Blood pressure increased—Docetaxel—melanoma	0.00208	0.00918	CcSEcCtD
Amphetamine—Acute coronary syndrome—Bleomycin—melanoma	0.00205	0.00903	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Temozolomide—melanoma	0.00205	0.00903	CcSEcCtD
Amphetamine—Myocardial infarction—Bleomycin—melanoma	0.00204	0.00898	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.00192	0.00847	CcSEcCtD
Amphetamine—Decreased appetite—Vemurafenib—melanoma	0.0019	0.00838	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00189	0.00832	CcSEcCtD
Amphetamine—Fatigue—Vemurafenib—melanoma	0.00189	0.00831	CcSEcCtD
Amphetamine—Constipation—Vemurafenib—melanoma	0.00187	0.00824	CcSEcCtD
Amphetamine—Lightheadedness—Docetaxel—melanoma	0.00186	0.00822	CcSEcCtD
Amphetamine—Erectile dysfunction—Temozolomide—melanoma	0.00181	0.00798	CcSEcCtD
Amphetamine—Depression—Carmustine—melanoma	0.00181	0.00797	CcSEcCtD
Amphetamine—Photosensitivity reaction—Temozolomide—melanoma	0.00179	0.00791	CcSEcCtD
Amphetamine—Weight decreased—Temozolomide—melanoma	0.00178	0.00784	CcSEcCtD
Amphetamine—Urinary tract infection—Carmustine—melanoma	0.00176	0.00777	CcSEcCtD
Amphetamine—Depression—Temozolomide—melanoma	0.00175	0.0077	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Temozolomide—melanoma	0.00174	0.00766	CcSEcCtD
Amphetamine—Body temperature increased—Vemurafenib—melanoma	0.00173	0.00762	CcSEcCtD
Amphetamine—Urinary tract infection—Temozolomide—melanoma	0.0017	0.00751	CcSEcCtD
Amphetamine—Erythema multiforme—Dactinomycin—melanoma	0.00164	0.00725	CcSEcCtD
Amphetamine—Hypersensitivity—Vemurafenib—melanoma	0.00161	0.0071	CcSEcCtD
Amphetamine—Lacosamide—SCN10A—melanoma	0.00158	0.0893	CrCbGaD
Amphetamine—Asthenia—Vemurafenib—melanoma	0.00157	0.00692	CcSEcCtD
Amphetamine—Diarrhoea—Vemurafenib—melanoma	0.0015	0.0066	CcSEcCtD
Amphetamine—Erythema multiforme—Temozolomide—melanoma	0.00149	0.00656	CcSEcCtD
Amphetamine—Dizziness—Vemurafenib—melanoma	0.00145	0.00637	CcSEcCtD
Amphetamine—Nateglinide—SLC15A2—melanoma	0.00142	0.0804	CrCbGaD
Amphetamine—Vomiting—Vemurafenib—melanoma	0.00139	0.00613	CcSEcCtD
Amphetamine—Chest pain—Bleomycin—melanoma	0.00138	0.00609	CcSEcCtD
Amphetamine—Abdominal pain upper—Docetaxel—melanoma	0.00138	0.00609	CcSEcCtD
Amphetamine—Rash—Vemurafenib—melanoma	0.00138	0.00608	CcSEcCtD
Amphetamine—Dermatitis—Vemurafenib—melanoma	0.00138	0.00607	CcSEcCtD
Amphetamine—Headache—Vemurafenib—melanoma	0.00137	0.00604	CcSEcCtD
Amphetamine—Toxic epidermal necrolysis—Docetaxel—melanoma	0.00136	0.006	CcSEcCtD
Amphetamine—Tremor—Carmustine—melanoma	0.00133	0.00585	CcSEcCtD
Amphetamine—Anaphylactic shock—Bleomycin—melanoma	0.00132	0.00584	CcSEcCtD
Amphetamine—Infection—Bleomycin—melanoma	0.00132	0.0058	CcSEcCtD
Amphetamine—Agitation—Carmustine—melanoma	0.0013	0.00574	CcSEcCtD
Amphetamine—Nausea—Vemurafenib—melanoma	0.0013	0.00573	CcSEcCtD
Amphetamine—Tremor—Temozolomide—melanoma	0.00128	0.00566	CcSEcCtD
Amphetamine—Anorexia—Bleomycin—melanoma	0.00126	0.00557	CcSEcCtD
Amphetamine—Agitation—Temozolomide—melanoma	0.00126	0.00555	CcSEcCtD
Amphetamine—Angioedema—Temozolomide—melanoma	0.00125	0.00552	CcSEcCtD
Amphetamine—Convulsion—Carmustine—melanoma	0.00123	0.00541	CcSEcCtD
Amphetamine—Infection—Dactinomycin—melanoma	0.00123	0.00541	CcSEcCtD
Amphetamine—Hypertension—Carmustine—melanoma	0.00122	0.00539	CcSEcCtD
Amphetamine—Palpitations—Temozolomide—melanoma	0.00121	0.00533	CcSEcCtD
Amphetamine—Chest pain—Carmustine—melanoma	0.00121	0.00532	CcSEcCtD
Amphetamine—Anxiety—Carmustine—melanoma	0.0012	0.0053	CcSEcCtD
Amphetamine—Convulsion—Temozolomide—melanoma	0.00119	0.00523	CcSEcCtD
Amphetamine—Weight decreased—Docetaxel—melanoma	0.00118	0.00521	CcSEcCtD
Amphetamine—Hypertension—Temozolomide—melanoma	0.00118	0.00521	CcSEcCtD
Amphetamine—Dyspnoea—Bleomycin—melanoma	0.00118	0.00521	CcSEcCtD
Amphetamine—Anorexia—Dactinomycin—melanoma	0.00118	0.00519	CcSEcCtD
Amphetamine—Anxiety—Temozolomide—melanoma	0.00116	0.00512	CcSEcCtD
Amphetamine—Stevens-Johnson syndrome—Docetaxel—melanoma	0.00116	0.00509	CcSEcCtD
Amphetamine—Decreased appetite—Bleomycin—melanoma	0.00115	0.00508	CcSEcCtD
Amphetamine—Infection—Carmustine—melanoma	0.00115	0.00506	CcSEcCtD
Amphetamine—Acute coronary syndrome—Docetaxel—melanoma	0.00115	0.00506	CcSEcCtD
Amphetamine—Myocardial infarction—Docetaxel—melanoma	0.00114	0.00504	CcSEcCtD
Amphetamine—Dry mouth—Temozolomide—melanoma	0.00114	0.00503	CcSEcCtD
Amphetamine—Tachycardia—Carmustine—melanoma	0.00113	0.00498	CcSEcCtD
Amphetamine—Anaphylactic shock—Temozolomide—melanoma	0.00112	0.00493	CcSEcCtD
Amphetamine—Infection—Temozolomide—melanoma	0.00111	0.00489	CcSEcCtD
Amphetamine—Anorexia—Carmustine—melanoma	0.0011	0.00486	CcSEcCtD
Amphetamine—Hyperhidrosis—Temozolomide—melanoma	0.00108	0.00476	CcSEcCtD
Amphetamine—Decreased appetite—Dactinomycin—melanoma	0.00107	0.00474	CcSEcCtD
Amphetamine—Fatigue—Dactinomycin—melanoma	0.00107	0.0047	CcSEcCtD
Amphetamine—Anorexia—Temozolomide—melanoma	0.00107	0.0047	CcSEcCtD
Amphetamine—Urticaria—Bleomycin—melanoma	0.00105	0.00464	CcSEcCtD
Amphetamine—Body temperature increased—Bleomycin—melanoma	0.00105	0.00462	CcSEcCtD
Amphetamine—Insomnia—Carmustine—melanoma	0.00105	0.00461	CcSEcCtD
Amphetamine—Dyspnoea—Carmustine—melanoma	0.00103	0.00455	CcSEcCtD
Amphetamine—Somnolence—Carmustine—melanoma	0.00103	0.00453	CcSEcCtD
Amphetamine—Insomnia—Temozolomide—melanoma	0.00101	0.00446	CcSEcCtD
Amphetamine—Gastrointestinal pain—Dactinomycin—melanoma	0.00101	0.00445	CcSEcCtD
Amphetamine—Decreased appetite—Carmustine—melanoma	0.00101	0.00443	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Carmustine—melanoma	0.000998	0.0044	CcSEcCtD
Amphetamine—Dyspnoea—Temozolomide—melanoma	0.000996	0.00439	CcSEcCtD
Amphetamine—Somnolence—Temozolomide—melanoma	0.000994	0.00438	CcSEcCtD
Amphetamine—Erythema multiforme—Docetaxel—melanoma	0.000989	0.00436	CcSEcCtD
Amphetamine—Constipation—Carmustine—melanoma	0.000989	0.00436	CcSEcCtD
Amphetamine—Dyspepsia—Temozolomide—melanoma	0.000984	0.00434	CcSEcCtD
Amphetamine—Abdominal pain—Dactinomycin—melanoma	0.000977	0.00431	CcSEcCtD
Amphetamine—Body temperature increased—Dactinomycin—melanoma	0.000977	0.00431	CcSEcCtD
Amphetamine—Hypersensitivity—Bleomycin—melanoma	0.000976	0.0043	CcSEcCtD
Amphetamine—Decreased appetite—Temozolomide—melanoma	0.000972	0.00428	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Temozolomide—melanoma	0.000965	0.00425	CcSEcCtD
Amphetamine—Fatigue—Temozolomide—melanoma	0.000964	0.00425	CcSEcCtD
Amphetamine—Constipation—Temozolomide—melanoma	0.000956	0.00421	CcSEcCtD
Amphetamine—Asthenia—Bleomycin—melanoma	0.000951	0.00419	CcSEcCtD
Amphetamine—Gastrointestinal pain—Carmustine—melanoma	0.000946	0.00417	CcSEcCtD
Amphetamine—Abdominal pain—Carmustine—melanoma	0.000914	0.00403	CcSEcCtD
Amphetamine—Body temperature increased—Carmustine—melanoma	0.000914	0.00403	CcSEcCtD
Amphetamine—Gastrointestinal pain—Temozolomide—melanoma	0.000914	0.00403	CcSEcCtD
Amphetamine—Hypersensitivity—Dactinomycin—melanoma	0.00091	0.00401	CcSEcCtD
Amphetamine—Urticaria—Temozolomide—melanoma	0.000888	0.00391	CcSEcCtD
Amphetamine—Asthenia—Dactinomycin—melanoma	0.000887	0.00391	CcSEcCtD
Amphetamine—Body temperature increased—Temozolomide—melanoma	0.000884	0.00389	CcSEcCtD
Amphetamine—Abdominal pain—Temozolomide—melanoma	0.000884	0.00389	CcSEcCtD
Amphetamine—Hypersensitivity—Carmustine—melanoma	0.000852	0.00376	CcSEcCtD
Amphetamine—Diarrhoea—Dactinomycin—melanoma	0.000845	0.00373	CcSEcCtD
Amphetamine—Vomiting—Bleomycin—melanoma	0.000842	0.00371	CcSEcCtD
Amphetamine—Rash—Bleomycin—melanoma	0.000835	0.00368	CcSEcCtD
Amphetamine—Dermatitis—Bleomycin—melanoma	0.000835	0.00368	CcSEcCtD
Amphetamine—Pseudoephedrine—TNF—melanoma	0.00083	0.0468	CrCbGaD
Amphetamine—Asthenia—Carmustine—melanoma	0.00083	0.00366	CcSEcCtD
Amphetamine—Hypersensitivity—Temozolomide—melanoma	0.000823	0.00363	CcSEcCtD
Amphetamine—Nateglinide—PPARG—melanoma	0.000815	0.046	CrCbGaD
Amphetamine—Palpitations—Docetaxel—melanoma	0.000805	0.00355	CcSEcCtD
Amphetamine—Asthenia—Temozolomide—melanoma	0.000802	0.00353	CcSEcCtD
Amphetamine—Diarrhoea—Carmustine—melanoma	0.000791	0.00349	CcSEcCtD
Amphetamine—Convulsion—Docetaxel—melanoma	0.000789	0.00348	CcSEcCtD
Amphetamine—Nausea—Bleomycin—melanoma	0.000787	0.00347	CcSEcCtD
Amphetamine—Hypertension—Docetaxel—melanoma	0.000786	0.00347	CcSEcCtD
Amphetamine—Vomiting—Dactinomycin—melanoma	0.000786	0.00346	CcSEcCtD
Amphetamine—Rash—Dactinomycin—melanoma	0.000779	0.00343	CcSEcCtD
Amphetamine—Chest pain—Docetaxel—melanoma	0.000775	0.00342	CcSEcCtD
Amphetamine—Dizziness—Carmustine—melanoma	0.000765	0.00337	CcSEcCtD
Amphetamine—Diarrhoea—Temozolomide—melanoma	0.000765	0.00337	CcSEcCtD
Amphetamine—Dry mouth—Docetaxel—melanoma	0.000758	0.00334	CcSEcCtD
Amphetamine—Anaphylactic shock—Docetaxel—melanoma	0.000743	0.00328	CcSEcCtD
Amphetamine—Dizziness—Temozolomide—melanoma	0.000739	0.00326	CcSEcCtD
Amphetamine—Infection—Docetaxel—melanoma	0.000738	0.00325	CcSEcCtD
Amphetamine—Vomiting—Carmustine—melanoma	0.000735	0.00324	CcSEcCtD
Amphetamine—Nausea—Dactinomycin—melanoma	0.000734	0.00324	CcSEcCtD
Amphetamine—Rash—Carmustine—melanoma	0.000729	0.00321	CcSEcCtD
Amphetamine—Dermatitis—Carmustine—melanoma	0.000729	0.00321	CcSEcCtD
Amphetamine—Tachycardia—Docetaxel—melanoma	0.000725	0.0032	CcSEcCtD
Amphetamine—Headache—Carmustine—melanoma	0.000725	0.00319	CcSEcCtD
Amphetamine—Vomiting—Temozolomide—melanoma	0.000711	0.00313	CcSEcCtD
Amphetamine—Anorexia—Docetaxel—melanoma	0.000708	0.00312	CcSEcCtD
Amphetamine—Rash—Temozolomide—melanoma	0.000705	0.00311	CcSEcCtD
Amphetamine—Dermatitis—Temozolomide—melanoma	0.000704	0.0031	CcSEcCtD
Amphetamine—Headache—Temozolomide—melanoma	0.0007	0.00309	CcSEcCtD
Amphetamine—Nausea—Carmustine—melanoma	0.000687	0.00303	CcSEcCtD
Amphetamine—Insomnia—Docetaxel—melanoma	0.000672	0.00296	CcSEcCtD
Amphetamine—Nausea—Temozolomide—melanoma	0.000664	0.00293	CcSEcCtD
Amphetamine—Dyspnoea—Docetaxel—melanoma	0.000663	0.00292	CcSEcCtD
Amphetamine—Somnolence—Docetaxel—melanoma	0.000661	0.00291	CcSEcCtD
Amphetamine—Dyspepsia—Docetaxel—melanoma	0.000654	0.00288	CcSEcCtD
Amphetamine—Decreased appetite—Docetaxel—melanoma	0.000646	0.00285	CcSEcCtD
Amphetamine—Gastrointestinal disorder—Docetaxel—melanoma	0.000642	0.00283	CcSEcCtD
Amphetamine—Fatigue—Docetaxel—melanoma	0.000641	0.00282	CcSEcCtD
Amphetamine—Constipation—Docetaxel—melanoma	0.000636	0.0028	CcSEcCtD
Amphetamine—Gastrointestinal pain—Docetaxel—melanoma	0.000608	0.00268	CcSEcCtD
Amphetamine—Abdominal pain—Docetaxel—melanoma	0.000588	0.00259	CcSEcCtD
Amphetamine—Body temperature increased—Docetaxel—melanoma	0.000588	0.00259	CcSEcCtD
Amphetamine—Hypersensitivity—Docetaxel—melanoma	0.000548	0.00241	CcSEcCtD
Amphetamine—Asthenia—Docetaxel—melanoma	0.000533	0.00235	CcSEcCtD
Amphetamine—Diarrhoea—Docetaxel—melanoma	0.000509	0.00224	CcSEcCtD
Amphetamine—Dizziness—Docetaxel—melanoma	0.000491	0.00217	CcSEcCtD
Amphetamine—Vomiting—Docetaxel—melanoma	0.000473	0.00208	CcSEcCtD
Amphetamine—Rash—Docetaxel—melanoma	0.000469	0.00207	CcSEcCtD
Amphetamine—Dermatitis—Docetaxel—melanoma	0.000468	0.00206	CcSEcCtD
Amphetamine—Headache—Docetaxel—melanoma	0.000466	0.00205	CcSEcCtD
Amphetamine—Nausea—Docetaxel—melanoma	0.000441	0.00195	CcSEcCtD
Amphetamine—Selegiline—ABCB1—melanoma	0.000327	0.0185	CrCbGaD
Amphetamine—Nateglinide—ALB—melanoma	0.000307	0.0173	CrCbGaD
Amphetamine—TAAR1—Signaling by GPCR—KRAS—melanoma	7.25e-05	0.000218	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—CYP1B1—melanoma	7.15e-05	0.000215	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—FGF2—melanoma	7.09e-05	0.000213	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—F2RL1—melanoma	7.06e-05	0.000212	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ABCB1—melanoma	6.95e-05	0.000209	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GNA11—melanoma	6.92e-05	0.000208	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GAB2—melanoma	6.92e-05	0.000208	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—F2R—melanoma	6.87e-05	0.000206	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—PIK3CA—melanoma	6.66e-05	0.0002	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EDNRB—melanoma	6.65e-05	0.0002	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GRM3—melanoma	6.64e-05	0.0002	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MDM2—melanoma	6.63e-05	0.000199	CbGpPWpGaD
Amphetamine—SLC6A3—Transmission across Chemical Synapses—HRAS—melanoma	6.55e-05	0.000197	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—ERBB2—melanoma	6.54e-05	0.000196	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCR4—melanoma	6.5e-05	0.000195	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PIK3CB—melanoma	6.45e-05	0.000194	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PLA2G6—melanoma	6.45e-05	0.000194	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—GNAQ—melanoma	6.43e-05	0.000193	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PRKCA—melanoma	6.4e-05	0.000192	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ERCC2—melanoma	6.35e-05	0.000191	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KISS1—melanoma	6.3e-05	0.000189	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GAB2—melanoma	6.28e-05	0.000189	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GNA11—melanoma	6.28e-05	0.000189	CbGpPWpGaD
Amphetamine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—melanoma	6.26e-05	0.000188	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—MAPK1—melanoma	6.25e-05	0.000188	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CXCL8—melanoma	6.2e-05	0.000186	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—HRAS—melanoma	6.16e-05	0.000185	CbGpPWpGaD
Amphetamine—SLC6A2—Transmembrane transport of small molecules—ALB—melanoma	6.12e-05	0.000184	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCR1—melanoma	6.1e-05	0.000183	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SKI—melanoma	6.1e-05	0.000183	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDKN1B—melanoma	6.05e-05	0.000182	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MC1R—melanoma	6.01e-05	0.00018	CbGpPWpGaD
Amphetamine—TAAR1—GPCR downstream signaling—AKT1—melanoma	5.99e-05	0.00018	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT3—melanoma	5.93e-05	0.000178	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CASP3—melanoma	5.93e-05	0.000178	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL2—melanoma	5.92e-05	0.000178	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCR4—melanoma	5.91e-05	0.000177	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—IL6—melanoma	5.89e-05	0.000177	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ABCB1—melanoma	5.88e-05	0.000177	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—GNAQ—melanoma	5.84e-05	0.000175	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLCB4—melanoma	5.8e-05	0.000174	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—VCAN—melanoma	5.79e-05	0.000174	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CCND1—melanoma	5.77e-05	0.000173	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCR7—melanoma	5.76e-05	0.000173	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GRM1—melanoma	5.76e-05	0.000173	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CTNNB1—melanoma	5.72e-05	0.000172	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SUFU—melanoma	5.61e-05	0.000169	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MMP9—melanoma	5.61e-05	0.000168	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—CDKN1A—melanoma	5.59e-05	0.000168	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PTEN—melanoma	5.57e-05	0.000167	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NFKB1—melanoma	5.55e-05	0.000167	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—TP53—melanoma	5.48e-05	0.000165	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC6A11—melanoma	5.45e-05	0.000164	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIP4K2A—melanoma	5.45e-05	0.000164	CbGpPWpGaD
Amphetamine—TAAR1—Signaling by GPCR—AKT1—melanoma	5.44e-05	0.000163	CbGpPWpGaD
Amphetamine—SLC6A3—Transmembrane transport of small molecules—ALB—melanoma	5.42e-05	0.000163	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PRKCA—melanoma	5.42e-05	0.000163	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT3—melanoma	5.39e-05	0.000162	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ERCC2—melanoma	5.37e-05	0.000161	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—MTAP—melanoma	5.3e-05	0.000159	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RHOB—melanoma	5.24e-05	0.000157	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—BCL2L11—melanoma	5.24e-05	0.000157	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—VEGFA—melanoma	5.03e-05	0.000151	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HDAC6—melanoma	5.03e-05	0.000151	CbGpPWpGaD
Amphetamine—SLC6A3—Neuronal System—HRAS—melanoma	5.02e-05	0.000151	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CG—melanoma	5.01e-05	0.000151	CbGpPWpGaD
Amphetamine—DRD2—Circadian rythm related genes—IL6—melanoma	5.01e-05	0.000151	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—EDN1—melanoma	4.99e-05	0.00015	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—STAT3—melanoma	4.98e-05	0.00015	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—NRAS—melanoma	4.97e-05	0.000149	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP17A1—melanoma	4.89e-05	0.000147	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CSF2—melanoma	4.87e-05	0.000146	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PPARG—melanoma	4.84e-05	0.000145	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCR2—melanoma	4.77e-05	0.000143	CbGpPWpGaD
Amphetamine—DRD2—GPCR ligand binding—CXCL8—melanoma	4.77e-05	0.000143	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK3—melanoma	4.76e-05	0.000143	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—LUM—melanoma	4.72e-05	0.000142	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PHGDH—melanoma	4.72e-05	0.000142	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RAC2—melanoma	4.69e-05	0.000141	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PRKCA—melanoma	4.67e-05	0.00014	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—HPSE—melanoma	4.63e-05	0.000139	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MYC—melanoma	4.63e-05	0.000139	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—WNT5A—melanoma	4.62e-05	0.000139	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFC—melanoma	4.62e-05	0.000139	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GNA11—melanoma	4.62e-05	0.000139	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CUBN—melanoma	4.55e-05	0.000137	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—MAPK1—melanoma	4.53e-05	0.000136	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—EGFR—melanoma	4.53e-05	0.000136	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EDN1—melanoma	4.53e-05	0.000136	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—FASN—melanoma	4.52e-05	0.000136	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—SLC5A5—melanoma	4.44e-05	0.000133	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CSF2—melanoma	4.43e-05	0.000133	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CD—melanoma	4.41e-05	0.000132	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SDHD—melanoma	4.39e-05	0.000132	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CSPG4—melanoma	4.39e-05	0.000132	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—BSG—melanoma	4.39e-05	0.000132	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—ALB—melanoma	4.35e-05	0.000131	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—RAC1—melanoma	4.33e-05	0.00013	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CD44—melanoma	4.29e-05	0.000129	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—GNAQ—melanoma	4.29e-05	0.000129	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—KRAS—melanoma	4.28e-05	0.000129	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GPAM—melanoma	4.25e-05	0.000128	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PRKCA—melanoma	4.24e-05	0.000127	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CG—melanoma	4.24e-05	0.000127	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAP2K2—melanoma	4.15e-05	0.000125	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—CYP1B1—melanoma	4.11e-05	0.000124	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PPARG—melanoma	4.09e-05	0.000123	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—F2R—melanoma	4.06e-05	0.000122	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—RAC1—melanoma	3.93e-05	0.000118	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—PIK3CA—melanoma	3.93e-05	0.000118	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EDNRB—melanoma	3.93e-05	0.000118	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CB—melanoma	3.84e-05	0.000115	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTK2B—melanoma	3.81e-05	0.000115	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTGS2—melanoma	3.81e-05	0.000114	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—TP53—melanoma	3.8e-05	0.000114	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CD—melanoma	3.73e-05	0.000112	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GAB2—melanoma	3.71e-05	0.000111	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GNA11—melanoma	3.71e-05	0.000111	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FLT1—melanoma	3.69e-05	0.000111	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—ALB—melanoma	3.68e-05	0.000111	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CG—melanoma	3.66e-05	0.00011	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—HRAS—melanoma	3.64e-05	0.000109	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PLA2G6—melanoma	3.62e-05	0.000109	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HDAC2—melanoma	3.49e-05	0.000105	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCR4—melanoma	3.49e-05	0.000105	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FOXO4—melanoma	3.49e-05	0.000105	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—IL6—melanoma	3.48e-05	0.000105	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—GNAQ—melanoma	3.45e-05	0.000104	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ABCB1—melanoma	3.39e-05	0.000102	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CG—melanoma	3.32e-05	9.98e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PTEN—melanoma	3.32e-05	9.97e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CB—melanoma	3.25e-05	9.76e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—VCAN—melanoma	3.25e-05	9.76e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SYK—melanoma	3.24e-05	9.74e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTGS2—melanoma	3.22e-05	9.67e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CD—melanoma	3.22e-05	9.66e-05	CbGpPWpGaD
Amphetamine—TAAR1—Signaling Pathways—AKT1—melanoma	3.21e-05	9.65e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ITGAV—melanoma	3.18e-05	9.56e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT3—melanoma	3.18e-05	9.56e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NGFR—melanoma	3.18e-05	9.56e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PRKCA—melanoma	3.12e-05	9.37e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ERCC2—melanoma	3.09e-05	9.29e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SOCS1—melanoma	2.95e-05	8.86e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAP2K1—melanoma	2.94e-05	8.83e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—S100B—melanoma	2.94e-05	8.83e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CD—melanoma	2.92e-05	8.78e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB4—melanoma	2.81e-05	8.45e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PTEN—melanoma	2.81e-05	8.44e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CB—melanoma	2.8e-05	8.42e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN2B—melanoma	2.79e-05	8.37e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP17A1—melanoma	2.74e-05	8.23e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CD86—melanoma	2.7e-05	8.1e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—CXCL8—melanoma	2.69e-05	8.1e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EDN1—melanoma	2.67e-05	8.04e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CSF2—melanoma	2.61e-05	7.85e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGF1—melanoma	2.61e-05	7.85e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GNA11—melanoma	2.59e-05	7.78e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—IL2—melanoma	2.58e-05	7.74e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—E2F1—melanoma	2.56e-05	7.69e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CB—melanoma	2.55e-05	7.65e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—FASN—melanoma	2.53e-05	7.61e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PDGFRA—melanoma	2.53e-05	7.61e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ITGB3—melanoma	2.51e-05	7.53e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PRKCA—melanoma	2.51e-05	7.53e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—SLC5A5—melanoma	2.49e-05	7.49e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—SPP1—melanoma	2.46e-05	7.38e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAP2K2—melanoma	2.45e-05	7.36e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—CXCL8—melanoma	2.45e-05	7.35e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CG—melanoma	2.44e-05	7.34e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—GNAQ—melanoma	2.41e-05	7.23e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CD44—melanoma	2.41e-05	7.23e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PPARG—melanoma	2.36e-05	7.08e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—PIK3CA—melanoma	2.34e-05	7.03e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL2—melanoma	2.34e-05	7.03e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TERT—melanoma	2.33e-05	7e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—RAC1—melanoma	2.32e-05	6.98e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—CYP1B1—melanoma	2.31e-05	6.93e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HIF1A—melanoma	2.23e-05	6.69e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CD—melanoma	2.15e-05	6.45e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KDR—melanoma	2.13e-05	6.4e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—ALB—melanoma	2.12e-05	6.37e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FN1—melanoma	2.05e-05	6.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NOTCH1—melanoma	2.01e-05	6.03e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—PIK3CA—melanoma	1.98e-05	5.95e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CD80—melanoma	1.97e-05	5.91e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CG—melanoma	1.96e-05	5.9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—APC—melanoma	1.96e-05	5.9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KIT—melanoma	1.96e-05	5.9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—NRAS—melanoma	1.96e-05	5.9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EGF—melanoma	1.94e-05	5.83e-05	CbGpPWpGaD
Amphetamine—MAOB—Metabolism—AKT1—melanoma	1.91e-05	5.75e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ABCB1—melanoma	1.9e-05	5.71e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAPK3—melanoma	1.88e-05	5.65e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CB—melanoma	1.87e-05	5.62e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTGS2—melanoma	1.85e-05	5.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—BRAF—melanoma	1.85e-05	5.54e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IGF1—melanoma	1.8e-05	5.4e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—MAPK1—melanoma	1.79e-05	5.37e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—EGFR—melanoma	1.79e-05	5.37e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PRKCA—melanoma	1.75e-05	5.25e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAP2K1—melanoma	1.74e-05	5.22e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ERCC2—melanoma	1.73e-05	5.21e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CD—melanoma	1.73e-05	5.18e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—PIK3CA—melanoma	1.71e-05	5.14e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—KRAS—melanoma	1.69e-05	5.08e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—FGF2—melanoma	1.65e-05	4.96e-05	CbGpPWpGaD
Amphetamine—SLC22A3—Metabolism—AKT1—melanoma	1.62e-05	4.86e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PTEN—melanoma	1.62e-05	4.86e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—PIK3CA—melanoma	1.55e-05	4.66e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MDM2—melanoma	1.55e-05	4.64e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—ERBB2—melanoma	1.52e-05	4.58e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CB—melanoma	1.5e-05	4.52e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CXCL8—melanoma	1.45e-05	4.34e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—HRAS—melanoma	1.44e-05	4.31e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN1B—melanoma	1.41e-05	4.24e-05	CbGpPWpGaD
Amphetamine—DRD2—GPCR downstream signaling—AKT1—melanoma	1.4e-05	4.2e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CASP3—melanoma	1.38e-05	4.16e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL2—melanoma	1.38e-05	4.15e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—IL6—melanoma	1.37e-05	4.13e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CG—melanoma	1.37e-05	4.11e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CCND1—melanoma	1.35e-05	4.05e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CTNNB1—melanoma	1.33e-05	4.01e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PPARG—melanoma	1.32e-05	3.97e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MMP9—melanoma	1.31e-05	3.93e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—CDKN1A—melanoma	1.3e-05	3.91e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PTEN—melanoma	1.3e-05	3.9e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NFKB1—melanoma	1.29e-05	3.89e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling by GPCR—AKT1—melanoma	1.27e-05	3.81e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CD—melanoma	1.2e-05	3.62e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—ALB—melanoma	1.19e-05	3.57e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—VEGFA—melanoma	1.17e-05	3.53e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—STAT3—melanoma	1.16e-05	3.49e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—NRAS—melanoma	1.16e-05	3.48e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—PIK3CA—melanoma	1.14e-05	3.43e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK3—melanoma	1.11e-05	3.34e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MYC—melanoma	1.08e-05	3.25e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—MAPK1—melanoma	1.06e-05	3.17e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—EGFR—melanoma	1.06e-05	3.17e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CB—melanoma	1.05e-05	3.15e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTGS2—melanoma	1.04e-05	3.12e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—KRAS—melanoma	9.98e-06	3e-05	CbGpPWpGaD
Amphetamine—CYP2A6—Metabolism—AKT1—melanoma	9.32e-06	2.8e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—PIK3CA—melanoma	9.17e-06	2.75e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PTEN—melanoma	9.07e-06	2.72e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—TP53—melanoma	8.87e-06	2.67e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—HRAS—melanoma	8.48e-06	2.55e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—IL6—melanoma	8.12e-06	2.44e-05	CbGpPWpGaD
Amphetamine—DRD2—Signaling Pathways—AKT1—melanoma	7.49e-06	2.25e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—PIK3CA—melanoma	6.4e-06	1.92e-05	CbGpPWpGaD
Amphetamine—CYP2D6—Metabolism—AKT1—melanoma	5.23e-06	1.57e-05	CbGpPWpGaD
